Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported a small mandated share sale linked to equity compensation. On this Form 4, he disposed of 246 shares of common stock at $46.426 per share on March 6, 2026, and held 54,799 shares afterward.
According to the footnote, the sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity plans. The transaction was executed as a “sell to cover” event and is characterized as non-discretionary rather than an elective open-market trade.
Twist Bioscience Corp officer Dennis Cho reported a small sale of 425 shares of common stock on March 6, 2026 at $46.426 per share. After the transaction, he directly held 138,257 shares. According to the footnote, the shares were sold solely to cover tax withholding on vested restricted stock units and were mandated under the company’s equity incentive plan, so they do not represent a discretionary trade.
Twist Bioscience Corp senior vice president of human resources Paula Green reported an automatic sale of company stock to cover taxes from vesting equity. On March 6, 2026, she sold 935 shares of common stock at $46.426 per share under a mandatory “sell to cover” arrangement. After this tax-related sale, she directly holds 124,401 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported selling 2,423 shares of common stock on 2026-03-06 at an average price of $46.426 per share. After this transaction, she directly holds 860,629 shares.
According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandated "sell to cover" arrangement, rather than as discretionary trades. She also continues to hold employee stock options, including an award exercisable for 64,950 shares of common stock at an exercise price of $67.8500 per share expiring on 2030-08-31.
Filer submitted a Form 144 notice describing proposed and recent sales of common stock by an affiliate. The filing lists a proposed restricted-stock vesting sale dated 03/05/2026 and multiple reported sales by Robert F. Werner on 12/08/2025, 02/03/2026, 02/04/2026, and 02/23/2026 with share amounts of 230, 175, 7,000, and 1,693 respectively.
Paula Green filed a Form 144 reporting proposed sales of Common stock. The notice lists several transactions and proposed dispositions by Paula Green, with sales recorded on 12/08/2025, 12/22/2025, 02/03/2026, 02/17/2026, and 02/23/2026. Examples include 39,404 shares on 02/17/2026 and 1,194 shares on 02/03/2026. The filing identifies the broker as Fidelity Brokerage Services LLC and lists a vesting event (restricted stock vesting) on 03/05/2026.
Dennis H. Cho reported sales of common stock and a proposed restricted-stock vesting sale tied to the issuer. The filing lists completed sales of 398 shares on 12/08/2025 ($13,085.28), 324 shares on 12/22/2025 ($11,196.14), 1,099 shares on 02/03/2026 ($51,186.47), 5,000 shares on 02/11/2026 ($249,650.00), and 844 shares on 02/23/2026 ($39,423.07). The record also shows 425 shares associated with a 03/05/2026 restricted stock vesting event.
TWST reported a Form 144 notice to sell 2,423 common shares. The filing lists the sale method as Restricted Stock Vesting with an issuer-sourced disposition date of 03/05/2026. The filing also lists multiple prior sales by Emily M. Leproust in 12/2025 through 02/2026 with individual share and dollar amounts shown as context.
Artisan Partners Asset Management and affiliated entities amended a Schedule 13G to report beneficial ownership of 6,217,213 shares of Twist Bioscience Corporation common stock, representing 10.1% of the class based on 01/27/2026. The filing states these shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership.
Twist Bioscience Corporation filed an amended quarterly report mainly to correct typographical errors in officer certifications, while re-filing its full results for the quarter ended December 31, 2025.
Revenue rose to $103.7 million, up 16.9% from $88.7 million, driven by growth in both DNA synthesis and protein solutions and NGS applications. Gross margin improved to 52.0% from 48.3%, and operating loss narrowed slightly to $32.9 million. Net loss was $30.5 million, or $0.50 per share, compared with a $31.6 million loss, or $0.53 per share, a year earlier. The company used $24.8 million of cash in operating activities and ended the quarter with $197.9 million in cash, cash equivalents, and short-term investments, which management believes will fund operations for at least one year. As of January 27, 2026, there were 61,311,704 common shares outstanding.